12 days agoDr. Bobby Reddy, MD - Pi Health - Developing Medicines Faster For Diverse PopulationsProgressPotentialAndPossibilities
2 days agoMark McDonough - CEO, Cyrex Labs - Early Detection & Monitoring Of Complex Immune ConditionsProgressPotentialAndPossibilities
25 days agoFrom Neurons to Networks: Whole Brain Emulation @ Vision Weekend 2025, Puerto Rico Foresight Institutenonvaxer420
7 days agoProgress, Potential, and Possibilities Weekly Re-Broadcast - 5/3/2025ProgressPotentialAndPossibilities
28 days agoProgress, Potential, and Possibilities Weekly Re-Broadcast - 4/13/25ProgressPotentialAndPossibilities
5 days agoDr. Manfred Stapff, MD, PhD - Real-World Evidence UnveiledProgressPotentialAndPossibilities
25 days agoThe application for the new generation of pan TRK inhibitor Zurletrectinib (ICP-seven hundred and twDTnewswire
25 days agoThe application for the new generation of pan TRK inhibitor Zurletrectinib (ICP-seven hundred and twDTnewswire
23 days agoFred Hutch Cancer Center Ends DEI Programs Amid Trump Executive Order and Ongoing LawsuitRightell
29 days agoDr. Peter Ordentlich, Ph.D. - CSO & Founder, Syndax Pharmaceuticals - Reimagining Cancer TreatmentProgressPotentialAndPossibilities
15 days agoInnoCare Pharma Yinuokai (Obutinib) has been approved as a first-line treatment for chronic lymphocyDTnewswire